Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3374354 | 0.89 | HTT (0.30) | SMN1; SMN2 | |
| SCHEMBL3376121 | 0.88 | SMN1; SMN2 (0.31) | MAPTSMN1; SMN2 | |
| SCHEMBL3370176 | 0.88 | — | — | |
| SCHEMBL28655068 | 0.86 | CYP2D6 (0.31) | MAPTSMN1; SMN2 | |
| SCHEMBL11073647 | 0.86 | CYP2D6 (0.31) | MAPTSMN1; SMN2 | |
| SCHEMBL3376480 | 0.82 | DNM1 (0.32) | MAPTSMN1; SMN2CA12CA1 | |
| SCHEMBL3377431 | 0.80 | MAPT (0.31) | MAPT | |
| SCHEMBL3373140 | 0.78 | — | — | |
| SCHEMBL3372778 | 0.73 | MAPT (0.32) | MAPTSMN1; SMN2 | |
| SCHEMBL3373687 | 0.73 | MAPT (0.33) | MAPTSMN1; SMN2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324091-A1 | Pyrazolone Derivative | KOWA COMPANY, LTD. (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-2172458-A1 | PYRAZOLONE DERIVATIVE | Kowa Company, Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324091-A1 | Pyrazolone Derivative | SERPINE1, SERPINC1, TFPI | MAPT 2810/4885SMN1; SMN2 1596/4885CA12 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.